Comments
Commented by Stefan Feulner on July 25th, 2023 | 09:45 CEST
Sartorius, BioNxt Solutions, CENIT AG - Attack from the Second Row
While some of the big caps have already reached new highs in the current stock market year 2023, many undiscovered second-tier stocks are still a long way off. At the same time, companies, most of which rely on disruptive technologies, possess powerful potential. If the ambitious goals are achieved, investors can expect above-average returns.
Read
Commented by André Will-Laudien on July 24th, 2023 | 08:20 CEST
BYD, Varta and FREYR - who will build the perfect battery? First Phosphate with a big deal!
E-mobility is still in its infancy globally, with just 25.9 million pure electric vehicles on the road out of around 1.3 billion vehicles worldwide. The share is, therefore, just under 2%. Nevertheless, sales are growing strongly, especially in China, Europe and the US. China is the most important production country for electric cars. It is forecast that around 13 million e-cars will be produced in the Middle Kingdom in 2023, more than in Germany and the US combined. The production costs of e-cars are still significantly higher than those of combustion engines. The main price drivers are the batteries, which use rare metals in their production. China's dominance in the field of battery innovations is currently still very pronounced. Where are the opportunities for investors?
Read
Commented by Stefan Feulner on July 24th, 2023 | 08:00 CEST
SAP, Altech Advanced Materials, Varta AG - Positive surprises
The first six months of the stock market year 2023 are already history and have been one of the more successful ones, despite uncertainties due to high inflation rates and growing geopolitical tensions. The German benchmark index DAX alone put in a performance of over 16%. The reporting season for the first half of the year is currently underway. Many companies were able to surprise positively, which should speak for further rising share prices.
Read
Commented by Nico Popp on July 20th, 2023 | 08:15 CEST
Turning point in uranium: ThyssenKrupp Nucera, GoviEx Uranium, Cameco
The energy issue is a concern for industry and citizens. Consumers, in particular, are now so unsettled that they have decided to wait and see. But passivity is not a good advisor. Within industry, it has long been clear that hydrogen is the key to climate neutrality - the successful IPO of ThyssenKrupp Nucera underscores this. But there are energy alternatives: An agreement between Canada and Ukraine shines a spotlight on uranium.
Read
Commented by Stefan Feulner on July 20th, 2023 | 07:30 CEST
Rheinmetall, Viva Gold, Palantir - Unstoppable
Remember the stock market adage, "Sell in May and go away"? Those who would have said goodbye to the stock market this year would have missed out on a lot. Driven by AI hype, the Nasdaq technology exchange alone rose by almost 25%, while the S&P 500 climbed by around 13%. The crypto and precious metals markets also ended their winter hibernation and are on the verge of striking buy signals.
Read
Commented by Fabian Lorenz on July 20th, 2023 | 07:00 CEST
Plug Power and ThyssenKrupp with hydrogen momentum! Profit with Globex Mining
Hydrogen and electromobility are gaining momentum once again. First, there was the successful IPO of ThyssenKrupp Nucera, followed by record sales at Nel ASA and record profits at BYD. Plug Power and Globex Mining should also benefit from the positive sentiment. Plug Power has jumped and gained over 10% in the last few days. Analysts see further upside potential. The same is true for Globex Mining, which, as a mining incubator in North America, was allowed to profit from the next commodity boom. Analysts see 100% upside potential for ThyssenKrupp shares.
Read
Commented by Nico Popp on July 19th, 2023 | 08:55 CEST
Battery technology - but sustainable! Volkswagen, First Phosphate, SMA Solar
Germany's former flagship industry is suffering: Shifts are being cut at the Volkswagen plant in Zwickau. The reason: customers remain reluctant to buy new cars. They are not yet convinced by many e-cars. Added to this is the price shock. Using three companies as examples, we explore how it could go on for car manufacturers like Volkswagen and how investors can still bet on e-mobility.
Read
Commented by Fabian Lorenz on July 19th, 2023 | 08:25 CEST
Nel share is unstoppable, but money is being made at BYD and Saturn Oil + Gas
Yesterday's quarterly figures from Nel were well received by the stock market. As a result, the share price reacted with a jump of over 8%. The hydrogen pureplay increased sales by 159% to NOK 475 million. The electrolyser business grew even more strongly. However, the net loss also rose significantly to NOK 342 million, but investors seemed to overlook this fact yesterday. The situation is different at BYD. The Company made a profit of billions in the first half of the year and continues to expand vigorously. The price war with Tesla does not seem to be leaving any impact. Oil producer Saturn Oil & Gas is also earning splendidly. In the first quarter, EBITDA increased by an impressive 332%. The Company aims to be debt-free by 2025. Will a substantial dividend come then?
Read
Commented by André Will-Laudien on July 19th, 2023 | 08:00 CEST
Cannabis 3.0 - will profits be made now? Canopy and Tilray under pressure, Cantourage Group positioned superbly
For a few days now, a long-neglected stock market segment has been attracting attention again: the cannabis industry. The North American industry protagonists Canopy and Tilray have recently attracted some stock market turnover again, but skepticism remains high. For those investors who did not exit in time, they had to write off around 95% of their investment in the last 2 years, and experts suspect that the revaluation of the former high-flyers is not yet complete. We take a look at the nebulous scenery of hemp speculation.
Read
Commented by Armin Schulz on July 19th, 2023 | 07:45 CEST
Pfizer, Cardiol Therapeutics, Bayer - Pharma facing turnaround despite drug shortages?
In mid-June, there was a shortage of 470 prescription drugs in Germany, according to the Federal Institute for Drugs and Medical Devices. However, not only Germany is suffering from a shortage, but all of Europe. Once again, the dependence on China is the underlying cause. The EU is seeking countermeasures, but this will be challenging because capped prices, bureaucracy and rising energy costs make a location like Germany seem less attractive. At the same time, demographic change means that society needs the pharmaceutical industry more and more urgently. Therefore, we look at three companies that aim to heal sick people.
Read